The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease

Journal of Clinical Gastroenterology

Volumn 46, Issue 6, 2012, Pages 457-467

  Mouzaki, Marialena ^a   Allard, Johane P ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

diet; fatty liver; NAFLD; nutrition; obesity

Indexed keywords

ACETIC ACID; ALPHA TOCOPHEROL; AMINOTRANSFERASE; ARACHIDIC ACID; ASCORBIC ACID; BUTYRIC ACID; CHOLINE; DISACCHARIDE; F BOX PROTEIN; FAS LIGAND; FATTY ACID SYNTHASE; FRUCTOSE; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 6; LINOLEIC ACID; MINERAL; MONOSACCHARIDE; OLIGOSACCHARIDE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID; PROPIONIC ACID; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; SHORT CHAIN FATTY ACID; SUGAR ALCOHOL; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANTIINFLAMMATORY ACTIVITY; BARIATRIC SURGERY; BEVERAGE; CARBOHYDRATE INTAKE; COMPUTER ASSISTED TOMOGRAPHY; COPPER DEFICIENCY; DIETARY INTAKE; DISEASE COURSE; FOOD FREQUENCY QUESTIONNAIRE; GENE EXPRESSION; GLUCOSE TOLERANCE; HUMAN; LIPID DIET; LIPID METABOLISM; LIPID OXIDATION; LIVER BIOPSY; LIVER FIBROSIS; MACRONUTRIENT; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRITIONAL REQUIREMENT; OBSERVATIONAL STUDY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN INTAKE; REVIEW; TREADMILL EXERCISE; ULTRASOUND;

ADIPOSE TISSUE; ADULT; ANIMALS; CHILD; DISEASE PROGRESSION; ENERGY INTAKE; FATTY LIVER; FOOD; HUMANS; IMMUNE SYSTEM; INTESTINES; MICRONUTRIENTS; MINERALS; MOTOR ACTIVITY; VITAMINS;

EID: 84862287327     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31824cf51e     Document Type: Review

References (125)

1. Brunt EM. Non-Alcoholic fatty liver disease: What's new under the microscope? Gut. 2011;60:1152-1158.
2. Bellentani S, Scaglioni F, Marino M, et al. Epidemiology of non-Alcoholic fatty liver disease. Dig Dis. 2010;28:155-161.
3. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-Alcoholic fatty liver disease and non-Alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285.
4. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-Aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology. 2011; 140:124-131.
5. Omagari K, Kadokawa Y, Masuda J, et al. Fatty liver in nonalcoholic non-overweight japanese adults: Incidence and clinical characteristics. J Gastroenterol Hepatol. 2002;17: 1098-1105.
6. Araujo LM, De Oliveira DA, Nunes DS. Liver and biliary ultrasonography in diabetic and non-diabetic obese women. Diabetes Metab. 1998;24:458-462.
7. Tominaga K, Kurata JH, Chen YK, et al. Prevalence of fatty liver in japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci. 1995; 40:2002-2009.
8. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118: 1388-1393.
9. Ong JP, Younossi ZM. Epidemiology and natural history of nafld and nash. Clin Liver Dis. 2007;11:1-16. vii.
10. Nobili V, Alisi A, Raponi M. Pediatric non-Alcoholic fatty liver disease: Preventive and therapeutic value of lifestyle intervention. World J Gastroenterol. 2009;15:6017-6022.
11. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology. 1990;12:1106-1110.
12. Berasain C, Betes M, Panizo A, et al. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut. 2000;47:429-435.
13. Ulitsky A, Ananthakrishnan AN, Komorowski R, et al. A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients. Obes Surg. 2010;20:685-691.
14. Sanyal AJ. Nash: A global health problem. Hepatol Res. 2011;41:670-674.
15. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the united states. Gastroenterology. 2011;141: 1249-1253.
16. Barritt ASt, Dellon ES, Kozlowski T, et al. The influence of nonalcoholic fatty liver disease and its associated comorbidities on liver transplant outcomes. J Clin Gastroenterol. 2011; 45:372-378.
17. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology. 2010;52:1836-1846.
18. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: Old questions and new insights. Science. 2011;332:1519-1523.
19. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Long term nutritional intake and the risk for non-Alcoholic fatty liver disease (nafld): A population based study. J Hepatol. 2007;47:711-717.
20. Sathiaraj E, Chutke M, Reddy MY, et al. A case-control study on nutritional risk factors in non-Alcoholic fatty liver disease in indian population. Eur J Clin Nutr. 2011;65:533-537.
21. Solga S, Alkhuraishe AR, Clark JM, et al. Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci. 2004;49: 1578-1583.
22. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-Alcoholic fatty liver disease in adults: A systematic review. J Hepatol. 2012;56:255-266.
23. Yasutake K, Nakamuta M, Shima Y, et al. Nutritional investigation of non-obese patients with non-Alcoholic fatty liver disease: The significance of dietary cholesterol. Scand J Gastroenterol. 2009;44:471-477.
24. Davis JN, Le KA, Walker RW, et al. Increased hepatic fat in overweight hispanic youth influenced by interaction between genetic variation in pnpla3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr. 2010;92:1522-1527.
25. Ricci G, Canducci E, Pasini V, et al. Nutrient intake in italian obese patients: Relationships with insulin resistance and markers of non-Alcoholic fatty liver disease. Nutrition. 2011; 27:672-676.
26. Vilar L, Oliveira CP, Faintuch J, et al. High-fat diet: A trigger of non-Alcoholic steatohepatitis? Preliminary findings in obese subjects. Nutrition. 2008;24:1097-1102.
27. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003;37: 909-916.
28. Cortez-Pinto H, Jesus L, Barros H, et al. How different is the dietary pattern in non-Alcoholic steatohepatitis patients? Clin Nutr. 2006;25:816-823.
29. Toshimitsu K, Matsuura B, Ohkubo I, et al. Dietary habits and nutrient intake in non-Alcoholic steatohepatitis. Nutrition. 2007;23:46-52.
30. Capristo E, Miele L, Forgione A, et al. Nutritional aspects in patients with non-Alcoholic steatohepatitis (nash). Eur Rev Med Pharmacol Sci. 2005;9:265-268.
31. Church TS, Kuk JL, Ross R, et al. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology. 2006;130:2023-2030.
32. Krasnoff JB, Painter PL, Wallace JP, et al. Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology. 2008;47:1158-1166.
33. Kistler KD, Brunt EM, Clark JM, et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol. 2011;106:460-468; quiz 469.
34. St George A, Bauman A, Johnston A, et al. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology. 2009;50:68-76.
35. Shah K, Stufflebam A, Hilton TN, et al. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity (Silver Spring). 2009;17:2162-2168.
36. Kantartzis K, Thamer C, Peter A, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-Alcoholic fatty liver disease. Gut. 2009;58:1281-1288.
37. Perseghin G, Lattuada G, De Cobelli F, et al. Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care. 2007;30:683-688.
38. Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in nonalcoholic fatty liver disease independent of weight loss. Gut. 2011;60:1278-1283.
39. Kawaguchi T, Shiba N, Maeda T, et al. Hybrid training of voluntary and electrical muscle contractions reduces steatosis, insulin resistance, and il-6 levels in patients with nafld: A pilot study. J Gastroenterol. 2011;46:746-757.
40. Van Der Heijden GJ, Wang ZJ, Chu ZD, et al. A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, hispanic adolescents. Obesity (Silver Spring). 2010;18:384-390.
41. Johnson NA, Sachinwalla T, Walton DW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology. 2009;50:1105-1112.
42. Devries MC, Samjoo IA, Hamadeh MJ, et al. Effect of endurance exercise on hepatic lipid content, enzymes, and adiposity in men and women. Obesity (Silver Spring). 2008; 16:2281-2288.
43. De Luis DA, Aller R, Izaola O, et al. Effect of two different hypocaloric diets in transaminases and insulin resistance in nonalcoholic fatty liver disease and obese patients. Nutr Hosp. 2010;25:730-735.
44. Haufe S, Engeli S, Kast P, et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology. 2011;53:1504-1514.
45. Ryan MC, Abbasi F, Lamendola C, et al. Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults. Diabetes Care. 2007;30:1075-1080.
46. Lim JS, Mietus-Snyder M, Valente A, et al. The role of fructose in the pathogenesis of nafld and the metabolic syndrome. Nat Rev Gastroenterol Hepatol. 2010;7:251-264.
47. Collino M. High dietary fructose intake: Sweet or bitter life? World J Diabetes. 2011;2:77-81.
48. Vos MB, Kimmons JE, Gillespie C, et al. Dietary fructose consumption among us children and adults: The third national health and nutrition examination survey. Medscape J Med. 2008;10:160.
49. Mager DR, Patterson C, So S, et al. Dietary and physical activity patterns in children with fatty liver. Eur J Clin Nutr. 2010;64:628-635.
50. Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for non-Alcoholic fatty liver disease. J Hepatol. 2008;48:993-999.
51. Polyzos SA, Toulis KA, Goulis DG, et al. Serum total adiponectin in nonalcoholic fatty liver disease: A systematic review and meta-Analysis. Metabolism. 2011;60:313-326.
52. Lustig RH. Fructose: Metabolic, hedonic, and societal parallels with ethanol. J Am Diet Assoc. 2010;110:1307-1321.
53. Abid A, Taha O, Nseir W, et al. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol. 2009;51:918-924.
54. Silbernagel G, Machann J, Unmuth S, et al. Effects of 4-week very-high-fructose/glucose diets on insulin sensitivity, visceral fat and intrahepatic lipids: An exploratory trial. Br J Nutr. 2011;106:79-86.
55. Sobrecases H, Le KA, Bortolotti M, et al. Effects of shortterm overfeeding with fructose, fat and fructose plus fat on plasma and hepatic lipids in healthy men. Diabetes Metab. 2010;36:244-246.
56. Nagai Y, Yonemitsu S, Erion DM, et al. The role of peroxisome proliferator-Activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. Cell Metab. 2009;9:252-264.
57. Teff KL, Grudziak J, Townsend RR, et al. Endocrine and metabolic effects of consuming fructose- and glucose-sweetened beverages with meals in obese men and women: Influence of insulin resistance on plasma triglyceride responses. J Clin Endocrinol Metab. 2009;94:1562-1569.
58. Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes. 2006;55(suppl 2):S9-S15.
59. Wei Y, Wang D, Topczewski F, et al. Fructose-mediated stress signaling in the liver: Implications for hepatic insulin resistance. J Nutr Biochem. 2007;18:1-9.
60. Dong XC, Copps KD, Guo S, et al. Inactivation of hepatic foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab. 2008;8:65-76.
61. Bergheim I, Weber S, Vos M, et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: Role of endotoxin. J Hepatol. 2008;48:983-992.
62. Haub S, Kanuri G, Volynets V, et al. Serotonin reuptake transporter (sert) plays a critical role in the onset of fructoseinduced hepatic steatosis in mice. Am J Physiol Gastrointest Liver Physiol. 2010;298:G335-G344.
63. Spruss A, Kanuri G, Wagnerberger S, et al. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology. 2009;50:1094-1104.
64. Song M, Schuschke DA, Zhou Z, et al. High fructose feeding induces copper deficiency in Sprague-Dawley rats: A novel mechanism for obesity related fatty liver. J Hepatol. 2012; 56:433-440.
65. Aigner E, Theurl I, Haufe H, et al. Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. Gastroenterology. 2008;135:680-688.
66. Klosterbuer A, Roughead ZF, Slavin J. Benefits of dietary fiber in clinical nutrition. Nutr Clin Pract. 2011;26: 625-635.
67. Meijer K, De Vos P, Priebe MG. Butyrate and other shortchain fatty acids as modulators of immunity: What relevance for health? Curr Opin Clin Nutr Metab Care. 2010;13:715-721.
68. Bouhnik Y, Achour L, Paineau D, et al. Four-week short chain fructo-oligosaccharides ingestion leads to increasing fecal bifidobacteria and cholesterol excretion in healthy elderly volunteers. Nutr J. 2007;6:42.
69. Jenkins DJ, Wolever TM, Taylor RH, et al. Glycemic index of foods: A physiological basis for carbohydrate exchange. Am J Clin Nutr. 1981;34:362-366.
70. Vega-Lopez S, Mayol-Kreiser SN. Use of the glycemic index for weight loss and glycemic control: A review of recent evidence. Curr Diab Rep. 2009;9:379-388.
71. Valtuena S, Pellegrini N, Ardigo D, et al. Dietary glycemic index and liver steatosis. Am J Clin Nutr. 2006;84:136-142; quiz 268-139.
72. Rocha R, Cotrim HP, Siqueira AC, et al. Non alcoholic fatty liver disease: Treatment with soluble fibres. Arq Gastroenterol. 2007;44:350-352.
73. Kok N, Roberfroid M, Robert A, et al. Involvement of lipogenesis in the lower vldl secretion induced by oligofructose in rats. Br J Nutr. 1996;76:881-890.
74. Daubioul C, Rousseau N, Demeure R, et al. Dietary fructans, but not cellulose, decrease triglyceride accumulation in the liver of obese zucker fa/fa rats. J Nutr. 2002;132:967-973.
75. Reimer RA, Grover GJ, Koetzner L, et al. The soluble fiber complex polyglycoplex lowers serum triglycerides and reduces hepatic steatosis in high-sucrose-fed rats. Nutr Res. 2011;31: 296-301.
76. Grover GJ, Koetzner L, Wicks J, et al. Effects of the soluble fiber complex polyglycoplex(r) (pgx(r)) on glycemic control, insulin secretion, and glp-1 levels in zucker diabetic rats. Life Sci. 2011;88:392-399.
77. Oh da Y, Lagakos WS. The role of g-protein-coupled receptors in mediating the effect of fatty acids on inflammation and insulin sensitivity. Curr Opin Clin Nutr Metab Care. 2011;14:322-327.
78. Conterno L, Fava F, Viola R, et al. Obesity and the gut microbiota: Does up-regulating colonic fermentation protect against obesity and metabolic disease? Genes Nutr. 2011;6: 241-260.
79. Schwiertz A, Taras D, Schafer K, et al. Microbiota and scfa in lean and overweight healthy subjects. Obesity (Silver Spring). 2010;18:190-195.
80. Al-Lahham SH, Roelofsen H, Priebe M, et al. Regulation of adipokine production in human adipose tissue by propionic acid. Eur J Clin Invest. 2010;40:401-407.
81. Ge H, Li X, Weiszmann J, et al. Activation of g proteincoupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology. 2008;149:4519-4526.
82. Hong YH, Nishimura Y, Hishikawa D, et al. Acetate and propionate short chain fatty acids stimulate adipogenesis via gpcr43. Endocrinology. 2005;146:5092-5099.
83. Bjursell M, Admyre T, Goransson M, et al. Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am J Physiol Endocrinol Metab. 2011;300:E211-E220.
84. Wanten GJ, Calder PC. Immune modulation by parenteral lipid emulsions. Am J Clin Nutr. 2007;85:1171-1184.
85. De Piano A, Prado WL, Caranti DA, et al. Metabolic and nutritional profile of obese adolescents with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2007;44: 446-452.
86. Gauthier MS, Favier R, Lavoie JM. Time course of the development of non-Alcoholic hepatic steatosis in response to high-fat diet-induced obesity in rats. Br J Nutr. 2006;95: 273-281.
87. De Meijer VE, Le HD, Meisel JA, et al. Dietary fat intake promotes the development of hepatic steatosis independently from excess caloric consumption in a murine model. Metabolism. 2010;59:1092-1105.
88. Charlton M, Krishnan A, Viker K, et al. Fast food diet mouse: Novel small animal model of nash with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol. 2011;301:G825-G834.
89. Shapiro H, Tehilla M, Attal-Singer J, et al. The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clin Nutr. 2011;30:6-19.
90. Oya J, Nakagami T, Sasaki S, et al. Intake of n-3 polyunsaturated fatty acids and non-Alcoholic fatty liver disease: A cross-sectional study in japanese men and women. Eur J Clin Nutr. 2010;64:1179-1185.
91. Allard JP, Aghdassi E, Mohammed S, et al. Nutritional assessment and hepatic fatty acid composition in nonalcoholic fatty liver disease (nafld): A cross-sectional study. J Hepatol. 2008;48:300-307.
92. Capanni M, Calella F, Biagini MR, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-Alcoholic fatty liver disease: A pilot study. Aliment Pharmacol Ther. 2006;23:1143-1151.
93. Vega GL, Chandalia M, Szczepaniak LS, et al. Effects of n-3 fatty acids on hepatic triglyceride content in humans. J Investig Med. 2008;56:780-785.
94. Spadaro L, Magliocco O, Spampinato D, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis. 2008;40:194-199.
95. Zhu FS, Liu S, Chen XM, et al. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol. 2008;14:6395-6400.
96. Michalik L, Auwerx J, Berger JP, et al. International union of pharmacology. Lxi. Peroxisome proliferator-Activated receptors. Pharmacol Rev. 2006;58:726-741.
97. Gonzalez-Periz A, Horrillo R, Ferre N, et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: A role for resolvins and protectins. Faseb J. 2009;23:1946-1957.
98. Ishii H, Horie Y, Ohshima S, et al. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific pten-deficient mice. J Hepatol. 2009;50: 562-571.
99. Levy JR, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in fischer 344 rats. Hepatology. 2004;39:608-616.
100. Yamazaki T, Nakamori A, Sasaki E, et al. Fish oil prevents sucrose-induced fatty liver but exacerbates high-safflower oil-induced fatty liver in ddy mice. Hepatology. 2007;46: 1779-1790.
101. Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by ppargamma agonists: A potential mechanism of insulin sensitization. Endocrinology. 2002;143:998-1007.
102. Svegliati-Baroni G, Candelaresi C, Saccomanno S, et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: Role of peroxisome proliferator-Activated receptor-Alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol. 2006;169:846-860.
103. Marsman HA, Heger M, Kloek JJ, et al. Reversal of hepatic steatosis by omega-3 fatty acids measured non-invasively by (1) h-magnetic resonance spectroscopy in a rat model. J Gastroenterol Hepatol. 2011;26:356-363.
104. Oh DY, Talukdar S, Bae EJ, et al. Gpr120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulinsensitizing effects. Cell. 2010;142:687-698.
105. Cankurtaran M, Kav T, Yavuz B, et al. Serum vitamin-E levels and its relation to clinical features in nonalcoholic fatty liver disease with elevated alt levels. Acta Gastroenterol Belg. 2006;69:5-11.
106. Vos MB, Ryan C, Patricia B, et al. Correlation of vitamin E, uric acid and diet composition with histologic features of pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2012;54:90-96.
107. Machado MV, Ravasco P, Jesus L, et al. Blood oxidative stress markers in non-Alcoholic steatohepatitis and how it correlates with diet. Scand J Gastroenterol. 2008;43:95-102.
108. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The tonic randomized controlled trial. JAMA. 2011;305:1659-1668.
109. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-1685.
110. Landrier JF, Gouranton E, El Yazidi C, et al. Adiponectin expression is induced by vitamin E via a peroxisome proliferator-Activated receptor gamma-dependent mechanism. Endocrinology. 2009;150:5318-5325.
111. Zeisel SH. Choline: Clinical nutrigenetic/nutrigenomic approaches for identification of functions and dietary requirements. World Rev Nutr Diet. 2010;101:73-83.
112. Fischer LM, daCosta KA, Kwock L, et al. Sex and menopausal status influence human dietary requirements for the nutrient choline. Am J Clin Nutr. 2007;85:1275-1285.
113. Spencer MD, Hamp TJ, Reid RW, et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology. 2011;140:976-986.
114. Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2011;8:35-44.
115. Raubenheimer PJ, Nyirenda MJ, Walker BR. A cholinedeficient diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in mice fed a high-fat diet. Diabetes. 2006;55:2015-2020.
116. Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-Alcoholic steatohepatitis and iron: Increased prevalence of mutations of the hfe gene in non-Alcoholic steatohepatitis. J Hepatol. 1999;31:421-429.
117. Fargion S, Mattioli M, Fracanzani AL, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96:2448-2455.
118. Yamamoto M, Iwasa M, Iwata K, et al. Restriction of dietary calories, fat and iron improves non-Alcoholic fatty liver disease. J Gastroenterol Hepatol. 2007;22:498-503.
119. Nelson JE, Wilson L, Brunt EM, et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology. 2011;53: 448-457.
120. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117:4425-4433.
121. Aigner E, Theurl I, Theurl M, et al. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr. 2008;87:1374-1383.
122. Fujita N, Miyachi H, Tanaka H, et al. Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis. Cancer Epidemiol Biomarkers Prev. 2009;18:424-432.
123. Imeryuz N, Tahan V, Sonsuz V, et al. Iron preloading aggravates nutritional steatohepatitis in rats by increasing apoptotic cell death. J Hepatol. 2007;47:851-859.
124. Silva M, Silva ME, De Paula H, et al. Iron overload alters glucose homeostasis, causes liver steatosis, and increases serum triacylglycerols in rats. Nutr Res. 2008;28:391-398.
125. Tan TC, Crawford DH, Jaskowski LA, et al. Altered lipid metabolism in hfe-knockout mice promotes severe nafld and early fibrosis. Am J Physiol Gastrointest Liver Physiol. 2011; 301:G865-G876.